Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease

Monday, July 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a presentation at the 2024 Alzheimer’s Association International Conference regarding CSF phosphoproteomics biomarker analysis from the Phase 2 SHINE clinical trial. The study aims to elucidate the role of CT1812 in treating Alzheimer’s disease. This research highlights the potential of CT1812 as a therapeutic option.
Price reaction · baseline $2.37 (2024-07-26 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
-43.9%
day 1
-53.6%
day 3 · peak
-62%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents promising biomarker analysis.
  • CT1812 shows potential in Alzheimer's treatment.
  • Research contributes to understanding Alzheimer's disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Cho E, Caldwell J, Pandey K, et al. CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease . Poster presented at 2024 Alzheimer’s Association International Conference (AAIC) ; Philadelphia, PA.

Frequently Asked Questions

What was presented at the 2024 AAIC?

A poster on CSF phosphoproteomics biomarker analysis from the Phase 2 SHINE trial.

What is the focus of the SHINE trial?

The trial focuses on elucidating the role of CT1812 in Alzheimer's disease.

Where was the AAIC held?

The 2024 Alzheimer’s Association International Conference was held in Philadelphia, PA.

Who were the authors of the study?

The study was authored by Cho E, Caldwell J, Pandey K, and others.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare CT1812 Alzheimer's disease biomarker analysis Phase 2 trial CSF phosphoproteomics
Last updated: Jul 29, 2024

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →